
Opinion|Videos|July 29, 2024
Out of Pocket Costs Associated with Biosimilar Use
The panel discusses out of pocket costs and the impact of the 340b program for various patient types.
Advertisement
Episodes in this series

Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Oral PCSK9 Inhibitor Enlicitide Matches Injectables in Lowering LDL Cholesterol
2
Improving Patient-Centered Cardiovascular Care for Older Adults
3
Introduction of Work Requirements to Medicaid Enrollment Could Destabilize Health: William Schpero, PhD, MPhil, MPH
4
Gefurulimab for MG Exhibits Lasting Efficacy, Safety in Topline PREVAIL Trial Data
5














































